Gilead’s U.S. Advancing Access® program provides assistance to patients in the United States who do not have insurance or who need financial assistance.

As part of this program, Gilead provides assistance for people who cannot afford to pay for Viread® (tenofovir disoproxil fumarate) for the treatment of HIV and chronic hepatitis B; Complera™ (emtricitabine/rilpivirine/tenofovir disoproxil fumarate); Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Emtriva® (emtricitabine) for the treatment of HIV; Hepsera® (adefovir dipivoxil) for the treatment of chronic hepatitis B; and Vistide® (cidofovir injection), a treatment for cytomegalovirus retinitis in patients with AIDS.

To find out if you are eligible for this patient assistance program, contact Advancing Access® at 1-800-226-2056 between 9:00 a.m. and 8:00 p.m. (Eastern).